about
Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy.LNA/DNA mixmer-based antisense oligonucleotides correct alternative splicing of the SMN2 gene and restore SMN protein expression in type 1 SMA fibroblastsIn silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in Duchenne muscular dystrophyExtensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs.Mutation types and aging differently affect revertant fiber expansion in dystrophic mdx and mdx52 mice.Impaired regenerative capacity and lower revertant fibre expansion in dystrophin-deficient mdx muscles on DBA/2 background.Current Translational Research and Murine Models For Duchenne Muscular Dystrophy.Exon skipping for nonsense mutations in Duchenne muscular dystrophy: too many mutations, too few patients?Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.Molecular characterization and expression pattern of the equine lactate dehydrogenase A and B genes.Molecular characterization and expression of the equine M(1) and M(2)-pyruvate kinase gene.Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.Effects of extracellular lactate on production of reactive oxygen species by equine polymorphonuclear leukocytes in vitro.Systemic Delivery of Morpholinos to Skip Multiple Exons in a Dog Model of Duchenne Muscular Dystrophy.Comparison of the phenotypes of patients harboring in-frame deletions starting at exon 45 in the Duchenne muscular dystrophy gene indicates potential for the development of exon skipping therapy.Deletion of exons 3-9 encompassing a mutational hot spot in the DMD gene presents an asymptomatic phenotype, indicating a target region for multiexon skipping therapy.Molecular characterization of glycogen synthase 1 and its tissue expression profile with type II hexokinase and muscle-type phosphofructokinase in horses.Antisense PMO cocktails effectively skip dystrophin exons 45-55 in myotubes transdifferentiated from DMD patient fibroblasts.Multiple Exon Skipping in the Duchenne Muscular Dystrophy Hot Spots: Prospects and ChallengesMolecular cloning and expression of bottlenose dolphin CD34
P50
Q33594805-27779582-7CD9-45B6-BF37-8A1A8D3A9032Q33807788-9E6DCEB5-0BA1-437E-A25C-64647148B3EDQ35588627-9B83B510-921D-44DB-B929-0E469C161534Q36297940-1503837C-832F-41C2-ADC5-CEC09B9B545BQ37042659-38FF5760-2F55-4D11-BA22-EF83E2626661Q37479592-3516FD5F-7123-4FCB-8EB3-DEB18AC629D9Q37610505-BC184DC2-1208-48C5-9781-FF76E56AB8DBQ38014906-E5153734-700A-473E-8CAF-F48EFDB236D0Q38174921-894A838F-B0A3-40BB-B450-8324B3478917Q42629359-E7AA7875-6EAE-45AF-B246-E1917C34DEC4Q42661298-528D07C1-A226-4E3A-8BE0-D4F98AAB4881Q45945952-3D6DF54F-2BB8-442C-AE7C-7CE168FCB6D3Q50243297-153BF8A5-0D5F-4F6A-9875-8C2DE8309398Q51079282-40EBB8D4-B638-47E4-94B9-E04BD2740960Q51264255-A5B96FAE-6EB4-49A5-B46C-6505A77253A5Q52984164-385208AE-041B-4DC6-A28A-B4964EBF9D2BQ54681620-30909E19-086F-44EB-98A5-812A4C95D805Q55284165-C2A558E0-69A9-4666-80DD-D4530D2B38E0Q60909992-F6DF2D3C-8472-47E6-97C4-844F23E19E68Q82729418-E0160708-4E3D-4D43-A89E-7AE84D4F33D2
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0003-1573-4819
@en
name
Yusuke Echigoya
@ast
Yusuke Echigoya
@en
Yusuke Echigoya
@es
Yusuke Echigoya
@nl
type
label
Yusuke Echigoya
@ast
Yusuke Echigoya
@en
Yusuke Echigoya
@es
Yusuke Echigoya
@nl
prefLabel
Yusuke Echigoya
@ast
Yusuke Echigoya
@en
Yusuke Echigoya
@es
Yusuke Echigoya
@nl
P108
P106
P31
P496
0000-0003-1573-4819